Excellence Kelyniam Global, Inc. Uplists to OTCID Market Tier
CANTON, Conn., Sept. 8, 2025 /PRNewswire/ — Kelyniam Global, Inc. (OTC: KLYG), a leading manufacturer of custom cranial and craniofacial implants, today announced that it’s share trading platform has been elevated to OTCID status on the OTC Markets Group platform. This designation underscores the Company’s commitment to transparency and compliance, providing investors with enhanced access to current financial information and market data.
Terrance Kurtenbach, Chief Financial Officer of Kelyniam said, “Only a select group of OTC companies qualify for OTCID status, as it demands regular financial reporting and compliance with OTC Markets’ criteria—a level of rigor that many OTC-listed entities do not meet. This distinction positions Kelyniam among a more transparent subset of the OTC ecosystem, potentially attracting a broader investor base and supporting long-term growth.
“We are very excited to have our shares moved to the elevated OTCID trading platform”, This achievement not only validates our operational discipline but also enhances our ability to communicate effectively with the investment community as we continue to innovate in the custom cranial implant space.”
“Unlike non-reporting tiers like Pink No Information or Expert Market, OTCID companies must maintain ongoing reporting obligations, including timely disclosures of financial statements and material events, which fosters greater investor confidence and facilitates more efficient trading. We applaud OTC Markets continued efforts to distinguish and elevated registrants with viable business operating models and robust governance and reporting standards in providing investors with reliable information and opportunity”
Kelyniam Global, Inc. remains focused on expanding its product portfolio, including its PEEK cranial implants with patented fixation, and regenerative products that include CustomizedBone© (hydroxy apatite) implants and the Osteopore line of implants.
About Kelyniam Global, Inc. Kelyniam Global, Inc. specializes in the rapid production of custom cranial and craniofacial implants made from PEEK, a biocompatible polymer. The Company collaborates with neurosurgeons worldwide to deliver high-quality, patient-specific implants with a turnaround time of 48 hours. Kelyniam is committed to advancing medical technology and improving patient outcomes through innovation and precision manufacturing. For more information, visit www.kelyniam.com.
Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected. Investors are cautioned not to place undue reliance on these forward-looking statements.
SOURCE Kelyniam Global Inc
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo…
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo…
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…
Label-verified GaraHerb ingredient disclosures, manufacturing and policy transparency details, and what consumers searching for GaraHerb…
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES…
An informational overview examining category context, publicly available product disclosures, and what consumers often consider…